July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Nascent Geographic Atrophy as a Surrogate Endpoint in Age-Related Macular Degeneration.
Author Affiliations & Notes
  • Robyn H Guymer
    Centre for Eye Research Australia, Melbourne, Victoria, Australia
    Surgery, University of Melbourne, Melbourne, Victoria, Australia
  • Myra McGuinness
    Centre for Eye Research Australia, Melbourne, Victoria, Australia
  • Lauren A Hodgson
    Centre for Eye Research Australia, Melbourne, Victoria, Australia
  • Chi D Luu
    Centre for Eye Research Australia, Melbourne, Victoria, Australia
    Surgery, University of Melbourne, Melbourne, Victoria, Australia
  • Zhichao Wu
    Centre for Eye Research Australia, Melbourne, Victoria, Australia
  • Footnotes
    Commercial Relationships   Robyn Guymer, None; Myra McGuinness, None; Lauren Hodgson, None; Chi Luu, None; Zhichao Wu, None
  • Footnotes
    Support  Supported by the National Health & Medical Research Council, Project grant, Early Career Fellowship, and Senior Research Fellowship, BUPA, and Ellex. The Centre for Eye Research Australia gain support of the Victorian Government through its Operational Infrastructure Support Program.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2214. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robyn H Guymer, Myra McGuinness, Lauren A Hodgson, Chi D Luu, Zhichao Wu; Nascent Geographic Atrophy as a Surrogate Endpoint in Age-Related Macular Degeneration.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2214. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is an urgent need to identify robust surrogate endpoints to improve the feasibility of early intervention trials in age-related macular degeneration (AMD). We evaluated the potential for optical coherence tomography (OCT) imaging defined nascent geographic atrophy (nGA) to serve as a surrogate endpoint for the clinical endpoint of color fundus photograph defined geographic atrophy (GA).

Methods : The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study was a 36-month, randomized-controlled trial of a sub-threshold laser treatment (SNL) in participants with bilateral large drusen without any multimodal imaging (MMI) signs of atrophy. OCT images were graded for nGA and GA and we evaluated the predictive ability and validity of nGA to serve as a surrogate clinical endpoint for GA. We evaluated 4 criteria required for a surrogate endpoint; (1) a significant effect of treatment on the surrogate (nGA), (2) a significant effect of treatment on the clinical endpoint (GA), (3) a significant correlation between the surrogate and clinical endpoint and (4) the effect of treatment on the clinical endpoint becomes non-significant after accounting for the surrogate endpoint.

Results : 292 participants were randomized to receive SNL (n = 147) or sham treatment (n = 145) in the LEAD study. 37 study eyes and 40 non-study eyes developed nGA and 12 study eyes and 11 non-study eyes developed GA over the 36m review. In the study eye, treatment with the SNL significantly reduced the rate of progression to nGA (adjusted HR = 0.43; 95% CI = 0.20 to 0.91; P= 0.028) and to GA (adjusted HR = 0.16; 95% CI = 0.04 to 0.72; P= 0.017), and the presence of nGA was significantly associated with an increased rate of progression to GA (adjusted HR = 55.16; 95% CI = 8.37 to 363.60; P< 0.001). After accounting for nGA in a multivariable model, SNL treatment no longer showed a statistically significant effect on the rate of progression to GA (HR = 0.15; 95% CI = 0.02 to 1.11; P= 0.063), indicating that the effect of treatment on progression to GA can be captured by the development of nGA.

Conclusions : These findings support the utility of nGA as a surrogate endpoint for GA in clinical trials for the early stages of AMD, and its use can substantially improve the feasibility of future intervention trials.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×